<DOC>
	<DOCNO>NCT02770521</DOCNO>
	<brief_summary>The aim study evaluate : - The safety tolerability single dose treprostinil give subcutaneously ( injection skin ) - The pharmacokinetic profile ( body absorbs , break , get rid ) single subcutaneous dose new LY900014 formulation healthy Japanese participant . The study two part . Participants may enroll one part .</brief_summary>
	<brief_title>A Study Treprostinil New Formulation LY900014 Healthy Japanese Participants</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Overtly healthy Japanese Body mass index ( BMI ) 18.5 25 kilogram per square meter ( kg/m² ) Fasting plasma glucose ≥71 milligram per deciliter ( mg/dL ) ( 3.9 millimoles per liter [ mmol/L ] ) &lt; 108 mg/dL ( 6.0 mmol/L ) ( Part B ) Have normal blood pressure , pulse rate , electrocardiogram ( ECG ) , blood urine laboratory test result acceptable study Are currently enrol clinical trial involve investigational product type medical research judge scientifically medically compatible study Have participate clinical trial involve investigational product within 30 day study entry . Have previously complete withdrawn study study investigate treprostinil LY900014 , previously receive investigational product Have use health problem laboratory test result ECG reading , opinion doctor , could make unsafe participate , could interfere understand result study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>